Cargando…

Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway

OBJECTIVE: The aim was to provide external validation of the Southend GCA probability score (GCAPS) in patients attending a GCA fast-track pathway (GCA FTP) in NHS Lanarkshire. METHODS: Consecutive GCA FTP patients between November 2018 and December 2020 underwent GCAPS assessment as part of routine...

Descripción completa

Detalles Bibliográficos
Autores principales: Melville, Andrew R, Donaldson, Karen, Dale, James, Ciechomska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765789/
https://www.ncbi.nlm.nih.gov/pubmed/35059557
http://dx.doi.org/10.1093/rap/rkab102
_version_ 1784634388066074624
author Melville, Andrew R
Donaldson, Karen
Dale, James
Ciechomska, Anna
author_facet Melville, Andrew R
Donaldson, Karen
Dale, James
Ciechomska, Anna
author_sort Melville, Andrew R
collection PubMed
description OBJECTIVE: The aim was to provide external validation of the Southend GCA probability score (GCAPS) in patients attending a GCA fast-track pathway (GCA FTP) in NHS Lanarkshire. METHODS: Consecutive GCA FTP patients between November 2018 and December 2020 underwent GCAPS assessment as part of routine care. GCA diagnoses were supported by US of the cranial and axillary arteries (USS), with or without temporal artery biopsy (TAB), and confirmed at 6 months. Percentages of patients with GCA according to GCAPS risk group, performance of total GCAPS in distinguishing GCA/non-GCA final diagnoses, and test characteristics using different GCAPS binary cut-offs were assessed. Associations between individual GCAPS components and GCA and the value of USS and TAB in the diagnostic process were also explored. RESULTS: Forty-four of 129 patients were diagnosed with GCA, including 0 of 41 GCAPS low-risk patients (GCAPS <9), 3 of 40 medium-risk patients (GCAPS 9–12) and 41 of 48 high-risk patients (GCAPS >12). Overall performance of GCAPS in distinguishing GCA/non-GCA was excellent [area under the receiver operating characteristic curve, 0.976 (95% CI 0.954, 0.999)]. GCAPS cut-off ≥10 had 100.0% sensitivity and 67.1% specificity for GCA. GCAPS cut-off ≥13 had the highest accuracy (91.5%), with 93.2% sensitivity and 90.6% specificity. Several individual GCAPS components were associated with GCA. Sensitivity of USS increased by ascending GCAPS risk group (nil, 33.3% and 90.2%, respectively). TAB was diagnostically useful in cases where USS was inconclusive. CONCLUSION: This is the first published study to describe application of GCAPS outside the specialist centre where it was developed. Performance of GCAPS as a risk stratification tool was excellent. GCAPS might have additional value for screening GCA FTP referrals and guiding empirical glucocorticoid treatment.
format Online
Article
Text
id pubmed-8765789
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-87657892022-01-19 Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway Melville, Andrew R Donaldson, Karen Dale, James Ciechomska, Anna Rheumatol Adv Pract Original Article OBJECTIVE: The aim was to provide external validation of the Southend GCA probability score (GCAPS) in patients attending a GCA fast-track pathway (GCA FTP) in NHS Lanarkshire. METHODS: Consecutive GCA FTP patients between November 2018 and December 2020 underwent GCAPS assessment as part of routine care. GCA diagnoses were supported by US of the cranial and axillary arteries (USS), with or without temporal artery biopsy (TAB), and confirmed at 6 months. Percentages of patients with GCA according to GCAPS risk group, performance of total GCAPS in distinguishing GCA/non-GCA final diagnoses, and test characteristics using different GCAPS binary cut-offs were assessed. Associations between individual GCAPS components and GCA and the value of USS and TAB in the diagnostic process were also explored. RESULTS: Forty-four of 129 patients were diagnosed with GCA, including 0 of 41 GCAPS low-risk patients (GCAPS <9), 3 of 40 medium-risk patients (GCAPS 9–12) and 41 of 48 high-risk patients (GCAPS >12). Overall performance of GCAPS in distinguishing GCA/non-GCA was excellent [area under the receiver operating characteristic curve, 0.976 (95% CI 0.954, 0.999)]. GCAPS cut-off ≥10 had 100.0% sensitivity and 67.1% specificity for GCA. GCAPS cut-off ≥13 had the highest accuracy (91.5%), with 93.2% sensitivity and 90.6% specificity. Several individual GCAPS components were associated with GCA. Sensitivity of USS increased by ascending GCAPS risk group (nil, 33.3% and 90.2%, respectively). TAB was diagnostically useful in cases where USS was inconclusive. CONCLUSION: This is the first published study to describe application of GCAPS outside the specialist centre where it was developed. Performance of GCAPS as a risk stratification tool was excellent. GCAPS might have additional value for screening GCA FTP referrals and guiding empirical glucocorticoid treatment. Oxford University Press 2021-12-15 /pmc/articles/PMC8765789/ /pubmed/35059557 http://dx.doi.org/10.1093/rap/rkab102 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Melville, Andrew R
Donaldson, Karen
Dale, James
Ciechomska, Anna
Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway
title Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway
title_full Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway
title_fullStr Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway
title_full_unstemmed Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway
title_short Validation of the Southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway
title_sort validation of the southend giant cell arteritis probability score in a scottish single-centre fast-track pathway
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765789/
https://www.ncbi.nlm.nih.gov/pubmed/35059557
http://dx.doi.org/10.1093/rap/rkab102
work_keys_str_mv AT melvilleandrewr validationofthesouthendgiantcellarteritisprobabilityscoreinascottishsinglecentrefasttrackpathway
AT donaldsonkaren validationofthesouthendgiantcellarteritisprobabilityscoreinascottishsinglecentrefasttrackpathway
AT dalejames validationofthesouthendgiantcellarteritisprobabilityscoreinascottishsinglecentrefasttrackpathway
AT ciechomskaanna validationofthesouthendgiantcellarteritisprobabilityscoreinascottishsinglecentrefasttrackpathway